Unaudited Condensed Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 18,451	$ 43,338,710		$ (15,712,414)	$ 27,644,747
Balance (in Shares) at Dec. 31, 2019	18,450,992
Issuance of common stock for accrued research and development expense	$ 221	1,131,792			1,132,013
Issuance of common stock for accrued research and development expense (in Shares)	220,666
Stock-based compensation		425,844			425,844
Foreign currency translation adjustment			(20,283)		(20,283)
Net loss				(3,797,198)	(3,797,198)
Balance at Mar. 31, 2020	$ 18,672	44,896,346	(20,283)	(19,509,612)	25,385,123
Balance (in Shares) at Mar. 31, 2020	18,671,658
Balance at Dec. 31, 2020	$ 22,535	71,648,453	(51,538)	(34,279,648)	$ 37,339,802
Balance (in Shares) at Dec. 31, 2020	22,534,874
Issuance of common stock for accrued research and development expense (in Shares)					24,315
Sale of common stock, net of offering costs	$ 2,140	28,021,424			$ 28,023,564
Sale of common stock, net of offering costs (in Shares)	2,140,000
Issuance of common stock for stock option exercises	$ 245	655,008			655,253
Issuance of common stock for stock option exercises (in Shares)	244,656
Issuance of common stock for warrant exercises	$ 444	179,768			180,212
Issuance of common stock for warrant exercises (in Shares)	444,751
Stock-based compensation		1,030,415			1,030,415
Foreign currency translation adjustment			(37,958)		(37,958)
Net loss				(7,654,575)	(7,654,575)
Balance at Mar. 31, 2021	$ 25,364	$ 101,535,068	$ (89,496)	$ (41,934,223)	$ 59,536,713
Balance (in Shares) at Mar. 31, 2021	25,364,281